Recomgen Biopharm

Recomgen Biopharm is a Chinese biopharmaceutical company specializing in the development and commercialization of recombinant protein therapeutics, primarily focusing on cardiovascular and cerebrovascular diseases. The company's flagship product, Pu Ruo Lan (recombinant human prourokinase), is a Class 1 innovative drug approved in China for the treatment of acute myocardial infarction. Recomgen operates as a key biologics subsidiary of Tasly Pharmaceutical Group, leveraging its proprietary mammalian cell expression platform to advance a pipeline targeting thrombolytic and oncology indications. The company maintains large-scale GMP manufacturing facilities in Beijing to support its commercial and clinical-stage programs. Its research efforts continue to expand the clinical utility of prourokinase into indications such as acute ischemic stroke and pulmonary embolism.